References
- The Agency for Technology Assessment and Tariff System. [ cited 2017 Aug 01]. Available from: www.aotm.gov.pl
- Kawalec P, Malinowski KP. Relating health technology assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis. Health Policy. 2016 Nov;120(11):1240–1248.
- Malinowski KP, Kawalec P, Trąbka W. Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012-2014. Health Policy. 2016 Nov;120(11):1249–1255.
- Health Technology Assessment Guidelines. Warsaw, 2016 Aug; [cited 2017 Aug 05]. Available from: http://www.aotm.gov.pl/www/wp-content/uploads/wytyczne_hta/2016/20161104_HTA_Guidelines_AOTMiT.pdf
- Regulation of the minister of health of 2 April 2012 on the minimum requirements to be satisfied by the analyses accounted for in the applications for reimbursement and setting the official sales price and for increasing the official sales price of a drug. Warsaw. 2013. Ministry of Health, Warsaw, Poland. [cited 2017 Aug 05]. Available from: http://wwwold.aotm.gov.pl/assets/files/wytyczne_hta/2012/Regulation_MoH_minimum_requirements_03042012_eng.pdf
- Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005 May;37(5):360–363.
- Niewada M, Polkowska M, Jakubczyk M, et al. What influences recommendations issued by the agency for health technology assessment in poland? A glimpse into decision makers’ preferences. Value Health Reg Issues. 2013;2(2):267–272.
- Houzelot D, Heng C, Perinaud A. Analysis of orphan drugs reimbursement in major European HTA agencies. Value Health. 2016;19(7):A602.
- Allen N, Walker SR, Liberti L, et al. Health Technology Assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England, and Scotland. Value Health. 2017 Mar;20(3):320–328.
- Allen N, Liberti L, Walker SR, et al. A comparison of reimbursement recommendations by European HTA Agencies: is there opportunity for further alignment? Front Pharmacol. 2017 Jun;30(8):384. DOI:10.3389/fphar.2017.00384.
- Kawalec P Recommendations and reimbursement status of orphan drugs in UE countries. ISPOR 18th Annual European Congress, Milan, Italy, 2015; 18: A678 .
- Bending M, Hutton J, McGrath C. A comparison of pharmaceutical reimbursement agencies’ processes and methods in France and Scotland. Int J Technol Assess Health Care. 2012 Apr;28(2):187–194.
- Charokopou M, Majer IM, de Raad J, et al. Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006–2013. Value Health. 2015;18:284–291.
- Mauskopf J, Chirila C, Birt J, et al. Drug reimbursement recommendations by the national institute for health and clinical excellence: have they impacted the national health service budget? Health Policy. 2013;110(April(1)):49–59.